Chemistry: analytical and immunological testing – Cancer
Patent
1993-03-17
1995-01-24
Housel, James C.
Chemistry: analytical and immunological testing
Cancer
435 4, 435 32, 424 9, 128749, 128898, G01N 3348
Patent
active
053842600
ABSTRACT:
The present invention involves a method for early detection of developing tamoxifen resistance in breast cancer. Tamoxifen is the drug of choice for hormonal therapy of a first recurrence of breast cancer, but its use is associated eventually with emergence of resistant tumors. Whereas initial treatment is usually followed by tumor regression, resistant tumors may actually resume growth under continued tamoxifen treatment. Because such growth may actually be augmented by the tamoxifen, it is essential to identify the onset of resistance as early as possible so alternative therapy may be promptly instituted. Monitoring increased levels of estrogenic tamoxifen isomers or estrogenic tamoxifen metabolites signals developing resistance.
REFERENCES:
patent: 4806464 (1989-02-01), Spelsberg
patent: 4919937 (1990-04-01), Mauvais-Jarvis et al.
patent: 5023234 (1991-06-01), Labrie
patent: 5030417 (1991-07-01), Spelsberg
patent: 5119827 (1992-06-01), Osborne et al.
Armstrong et al., "Separation of tamoxifen geometric isomers and metabolites by bonded-phase .beta.-cyclodextrin chromatography," Journal of Chromatograpy, (1987) 414:192-196, published in Europe.
Katzenellenbogen et al., "Facile Geometric Isomerization of Phenolic Non-Steroidal Estrogens and Antiestrogens: Limitations to the Interpretation of Experiments Characterizing The Activity of Individual Isomers," J. Steroid Biochem., (1985) 22(5):589-596, published in Europe.
Katzenellenbogen et al., "Bioactivities, Estrogen Receptor Interactions, and Plasminogen Activator-inducing Activities of Tamoxifen and Hydroxytamoxifen Isomers in MCF-7 Human Breast Cancer Cells," Cancer Research, (1984) 44:112-119, published in the U.S.A.
Robertson et al., "Tamoxifen Antiestrogens. A Comparison of the Activity, Pharmacokinetics, and Metabolic Activation of the Cis and Trans Isomers of Tamoxifen," J. Steroid Biochem. (1982) 16:1-13, published in Europe.
Jordan, et al., "Geometric Isomers of Substituted Triphenylethylenes and Antiestrogen Action," Endocrinology (1981) 108(4):1353-1361, published in U.S.A.
V. C. Jordan, "Antiestrogenic and Antitumor Properties of Tamoxifen in Laboratory Animals," Cancer Treatment Reports (1976) 60(10):1409-1419, published in the U.S.A.
Fromson, et al., "The Matabolism of Tamoxifen* (I.C.I. 46, 474) Part II: In Female Patients," Xenobiotica (1973) 3(11):711-714, published in Europe.
Fromson, et al., "The Metabolism of Tamoxifen* (I.C.I. 46, 474) Part I: In Laboratory Animals," Xenobiotica (1973) 3(11):693-709, published in Europe.
L. Terenius, "Structure-Activity Relationships of Anti-Oestrogens With Regard To Interaction With 17.beta.-Oestradiol In The Mouse Uterus And Vagina," Acta Endocrinologica (1971) 66:431-447, published in Europe.
Harper and Walpole, "A New Derivative of Triphenylethylene: Effect on Implantation and Mode of Action in Rats," J. Reprod. Fert. (1967) 13:101-119, published in Europe.
Medline Search Report, (1990), printed in U.S.A.
Dialog Search Report, (1990), printed in U.S.A.
Murphy et al., "Structure-Function Relationships of Hydroxylated Metabolites of Tamoxifen that Control the Proliferation of Estrogen-Responsive T47D Breast Cancer Cells In Vitro", Mole. Pharm. (1990) 38:737-743, published in U.S.A.
Simon et al., "Development of Resistance To Tamoxifen And Progestins In Human Mammary Cancer," Proc. Int. Congr. Chemuther. (1983) 18:270/1-4, published in U.S.A.
Jordan et al., "Ligand Interaction at the Estrogen Receptor to Program Antiestrogen Action: A Study With Nonsteroidal Compounds in Vitro*," Endocrinology (1988) 122(4):1449-1454, published in U.S.A.
Jordan et al., "Ligand Interaction at the Estrogen Receptor to Program Antiestrogen Action: A Study with Nonsteroidal Compounds In Vitro," Chemical Abstracts, (1988) 108:198501d, published in U.S.A.
Jordan et al., "Ligand Interaction at the Estrogen Receptor to Program Antiestrogen Action: A Study with Nonsteroidal Compounds In Vitro," Dialog Printout, (1991), printed in USA.
Murphy et al., "Structure-Function Relationships of Hydroxylated Metabolites of Tamoxifen that Control the Proliferation of Estrogen-Responsive T47D Breast Cancer Cells In Vitro", Dialog Printout (1991), printed in U.S.A.
Murphy et al., "Structure-Function Relationships of Hydroxylated Metabolites of Tamoxifen that Control the Proliferation of Estrogen-Responsive T47D Breast Cancer Cells In Vitro", Chemical Abstracts (1991) 114:55296d, published in U.S.A.
Jordan et al., "Resistance to Antiestrogen Therapy" in Drug Resistance, D. Kessle (ed.), CRC Press, Boca Raton, Fla., 1987, pp. 403-427.
DeGregorio Michael W.
Osborne C. Kent
Board of Regents , The University of Texas System
Housel James C.
Wallen Maureen M.
Yale University
LandOfFree
Detection of onset of antiestrogen resistance in breast cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection of onset of antiestrogen resistance in breast cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of onset of antiestrogen resistance in breast cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1468269